Alexion Pharmaceuticals EBIT

Alexion Pharmaceuticals (ALXN) currently reports a EBIT of $2.9B as of March 2021. That compares with $2.4B in the prior-year period — up 23.8% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Alexion Pharmaceuticals's EBIT history and peer comparisons.

Alexion Pharmaceuticals's EBIT increased from $2.4B to $2.9B — a 23.8% year-over-year increase (period ending March 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alexion Pharmaceuticals's EBIT of $2.9B is lower than the Healthcare sector average of $23B. That is roughly 87.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Alexion Pharmaceuticals reported $2.9B in EBIT as of March 2021. That compares with $2.4B in the prior-year period — up 23.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $2.9B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Alexion Pharmaceuticals, and consider following ALXN for alerts when major investors trade the stock.